InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), today announced that, further to the Company’s prior reports regarding growing demand in Germany and opportunities arising from the recent U.S. federal rescheduling of cannabis, the Company has entered into a binding term sheet providing for funding commitments of NIS 22 million (approximately US$7.4 million), which may increase to NIS 54 million (approximately US$18.6 million) (the "Private Placement").

The funding includes investment commitments from certain investors, including the Company’s Chief Executive Officer, Mr. Alexander Rabinovich, as well as leading institutional investment funds, including Bennu Pharma Fund Ltd. In the Private Placement, InterCure has agreed to issue to the investors (i) an aggregate of 7,895,143 ordinary shares of the Company, at a purchase price of NIS 2.75 (approximately US$0.94) per ordinary share, representing a premium over the closing price of InterCure’s ordinary shares on the Tel Aviv Stock Exchange on Wednesday, June 17, 2026, which was NIS 2.69 per share (the "Determining Date"), and (ii) warrants (the "Warrants") to purchase up to an additional 7,895,143 ordinary shares of the Company at an exercise price of NIS 4.125 per share (approximately US$1.41), representing an approximately 53% premium over the closing price of InterCure’s ordinary shares on the Determining Date, which may further increase the proceeds from the private placement up to a total of approximately NIS 54 million (approximately US$18.6 million) if fully exercised for cash. The Warrants will be exercisable for a period of five years from the date of issuance. The securities to be issued in the Private Placement will be subject to applicable restrictions on transfer. The terms of the Private Placement were determined through negotiations between the Company and the investors, based on the closing share price on the Determining Date. The Private Placement is subject to entry into definitive documentation and will be subject to certain closing conditions, including in the case of Mr. Rabinovich’s investment, approval of InterCure’s shareholders.